Further PoC studies by Hudson Institute are ongoing, including a larger TNBC study (primary
tumour model), as well as secondary study investigating the potential of INV043 to treat
metastatic disease. Each study will include arms exploring potential synergies with other
cancer therapies.
Dated 28th Oct 2021
They should release these results before they start clinical trials, IMHO.
Ann: Complete Regression of TNBC Tumours and Protective Immunity, page-254
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 12.0¢ | $9.468K | 78.89K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10898 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 85917 | 1 |
View Market Depth
| Last trade - 10.10am 25/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |